BeiGene announces new appointments

Yesterday, BeiGene announced that Alessandro Riva has been appointed as co-chair of the Board's Scientific Advisory Committee (the "Scientific Advisory Committee"), effective November 20, 2022. Corazon (Corsee) D. Sanders will no longer serve as co-chair of the Scientific Advisory Board, but will continue to serve as a member of the Scientific Advisory Board.

Since then, the Scientific Advisory Board has consisted of seven members, including Dr. Margaret Han Dugan, Mr. Michael Goller, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Dr. Wang Xiaodong and Mr. Yi Qingqing. Dr. Xiaodong Wang and Dr. Alessandro Riva are co-chairs of the Scientific Advisory Board.

Alessandro Riva, co-chair of the new Scientific Advisory Board, has served on BeiGene's board of directors since February. Alessandro Riva also currently serves as CEO of Intima Bioscience, a privately held clinical-stage gene and cell therapy company. Alessandro Riva also serves on the board of directors of Century Therapeutics, a NASDAQ-listed biotechnology company that develops innovative iPSC-derived NK and T cell therapies.

Previously, Alessandro Riva received his Doctor of Medicine and Surgical Medicine degree from the University of Milan, where he obtained his Specialist License certified by the Board of Oncology and Hematology. He previously served as Executive Vice President and Global Head of Oncology Development and Medical Affairs at Novartis and Executive Vice President and Global Head of Oncology Therapeutics, Cell and Gene Therapy at Gilead Technologies.

BeiGene's Board of Directors established a Scientific Advisory Committee on February 26, 2020 to assist the Board in overseeing the Company's R&D activities and advising the Board on scientific considerations that should be considered at a strategic level, according to Zhitong Finance.